Anti-CCP antibodies measured at disease onset help identify seronegative rheumatoid arthritis and predict radiological and functional outcome

Rheumatology

Volumn 45, Issue 4, 2006, Pages 478-480

  Quinn, Mark A ^a   Gough, A K S ^a   Green, M J ^a   Devlin, J ^a   Hensor, E M A ^a   Greenstein, A ^a   Fraser, A ^a   Emery, P ^a  

^a CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

Anti CCP antibodies; Early rheumatoid arthritis

Indexed keywords

C REACTIVE PROTEIN; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; EPITOPE; RHEUMATOID FACTOR;

ADULT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DIAGNOSTIC VALUE; DISEASE DURATION; FEMALE; FUNCTIONAL ASSESSMENT; HLA TYPING; HUMAN; JOINT RADIOGRAPHY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; SYMPTOMATOLOGY;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; C-REACTIVE PROTEIN; COHORT STUDIES; DISABILITY EVALUATION; FEMALE; HLA-DR ANTIGENS; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; PROGNOSIS; RHEUMATOID FACTOR; SENSITIVITY AND SPECIFICITY; SYNOVITIS;

EID: 33645345411     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kei203     Document Type: Article

References (23)

1. Boers M. Understanding the window of opportunity concept in early rheumatoid arthritis. Arthritis Rheum 2003;48:1771-4.
2. Quinn MA, Emery P. Window of opportunity in early rheumatoid arthritis: possibility of altering the disease process with early intervention. Clin Exp Rheumatol 2003;21(Suppl. 31):S154-7.
3. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: What is the evidence? Rheumatology 2001;40:1211-20.
4. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;3:315-24.
5. Green MJ M-OH, McGonagle et al. Persistence of mild early inflammatory arthritis: The importance of disease duration, rheumatoid factor and the shared epitope. Arthritis Rheum 1999;42:2184-8.
6. Harrison BJ, Symmons DPM, Barrett EM, Silman AJ. The performance of the 1987 ARA classification criteria for rheumatoid arthritis in a population based cohort of patients with early inflammatory arthritis. J Rheumatol 1998;25:2324-30.
7. Emery P. The optimal management of early rheumatoid disease: The key to preventing disability. Br J Rheumatol 1994;33:765-8.
8. van der Heide A, Jacobs JW, Haanen HC, Bijlsma JW. Is it possible to predict the first year extent of pain and disability for patients with rheumatoid arthritis? J Rheumatol 1995;22:1466-70.
9. Möttönnen T, Paimela L, Leirisalo-Repo M, Kautiainen H, Ilonen J, Hannonen P. Only high disease activity and positive rheumatoid factor indicate poor prognosis in patients with rheumatoid arthritis treated with 'saw-tooth' strategy. Ann Rheum Dis 1998;57:533-9.
10. Harrison B, Thomson W, Symmons D et al. The influence of HLA-DRB1 alleles and rheumatoid factor on disease outcome in an inception cohort of patients with early inflammatory arthritis. Arthritis Rheum 1999;42:2174-83.
11. van Zeben D, Hazes JM, Zwinderman AH, Cats A, van der Voort EA, Breedveld FC. Clinical significance of rheumatoid factors in early rheumatoid arthritis: Results of a follow up study. Ann Rheum Dis 1992;51:1029-35.
12. Schellekens GA, Visser H, de Jong BAW et al. The diagnostic properties of rheumatoid arthritis antibodies recognising a cyclic citrullinated peptide. Arthritis Rheum 2000;43:155-63.
13. Bizzaro N, Mazzanti G, Tonutti E, Villalta D, Tozzoli R. Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clin Chem 2001;47:1089-93.
14. van Venrooij WJ, van Boekel MAM, van den Hoogen FHJ, Drijfhourt JW. De 2de generatie anti-CCP test voor de vroege detectie van reumatoide arthritis. Ned T Rheum 2002;2:6-10.
15. Meyer O, Labarre C, Dougados M et al. Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-6.
16. van Jaarsveld CH, ter Borg EJ, Jacobs JW et al. The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clin Exp Rheum 1999;17:689-97.
17. Kroot EJ, de Jong BAW, van Leeuwen MA et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
18. Pincus T, Summey JA, Soraci SA Jr et al. Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis Rheum 1983; 26:1346-53.
19. Gough A, Faint J, Salmon M et al. Genetic typing of patients with inflammatory arthritis at presentation can be used to predict outcome. Arthritis Rheum 1994;37:1166-70.
20. Hoffman IEA, Peene I, Cebecauer L et al. Presence of rheumatoid factor and antibodies to citrullinated peptides in systemic lupus erythematosus. Ann Rheum Dis 2005;64:330-2.
21. Rantapaa-Dahlqvist S, de Jong BA, Berglin E et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
22. van Gaalen FA, van Aken J, Huizinga TWJ et al. Association between HLA class II genes and autoantibodies to cyclic citrullinated peptides (CCPs) influence the severity of rheumatoid arthritis. Arthritis Rheum 2004;50:2113-21.
23. Berglin E, Padyukov L, Sundin U et al. A combination of autoantibodies to cyclic citrullinated peptide (CCP) and HLA DRB-1 locus antigens is strongly associated with future onset of rheumatoid arthritis. Arthritis Res Ther 2004;6:R303-8.